Phase I study of the mitomycin C analogue BMS-181174.

BMS-181174 is an aminodisulphide derivative of Mitomycin C (MMC) with activity against a range of tumour cell lines and xenografts, including MMC-resistant tumours. In a phase I study of 82 patients with confirmed malignancy, we administered BMS-181174 at doses of 0.8-75 mg m(-2) by intravenous inje...

Descripción completa

Detalles Bibliográficos
Autores principales: Macaulay, V. M., O'Byrne, K. J., Green, J. A., Philip, P. A., McKinley, L., LaCreta, F. P., Winograd, B., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150373/
https://www.ncbi.nlm.nih.gov/pubmed/9667686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150373/
https://www.ncbi.nlm.nih.gov/pubmed/9667686

Ejemplares similares